| Filed On | Filing |
|---|---|
| 26 Oct 2026 | RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA |
| 26 Oct 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 26 Oct 2026 | JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE |
| 26 Oct 2026 | POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER |
| 21 Oct 2026 | US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B |
| 19 Oct 2026 | JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER |
| 19 Oct 2026 | RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER |
| 15 Oct 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 14 Oct 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 13 Oct 2026 | S-8 |
| 13 Oct 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 13 Oct 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 08 Oct 2026 | WENDY BECKER CBE - NEW DIRECTORSHIP |
| 06 Oct 2026 | ADMISSION TO TRADING |
| 01 Oct 2026 | TOTAL VOTING RIGHTS |
| 24 Sep 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 22 Sep 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 22 Sep 2026 | NYSE CERTIFICATION |
| 15 Sep 2026 | 8-A12B |
| 15 Sep 2026 | 6-K |
Loading...
